| Literature DB >> 23233023 |
Y Tatebayashi1, N Nihonmatsu-Kikuchi, Y Hayashi, X Yu, M Soma, K Ikeda.
Abstract
Bipolar and major depressive disorders are essentially relapsing and remitting disorders of affect with nearly full recovery between episodes. Although the underlying molecular mechanisms remain unclear, myelin-related abnormalities have long been suspected. Here, using novel statistical analysis, we show that subtle but significant abnormalities exist in the composition of fatty acids (FAs), including docosapentaenoic acid (22:5n-3), one of the omega-3 polyunsaturated FAs, found in the post-mortem frontopolar cortex (FPC) of subjects with bipolar or major depressive disorders, although not in those with schizophrenia. These abnormalities were all aggravated in a myelin level-dependent manner, suggesting their close relationship with myelination. Animal studies have further revealed that chronic antidepressant treatment induces robust changes in brain FA metabolism, but contributes only part of the abnormalities found in the affective disorder brains. These findings indicate that the pathophysiology of affective disorders involves an unknown type of perturbed myelination in the FPC that may serve as a novel diagnostic and therapeutic target.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23233023 PMCID: PMC3565193 DOI: 10.1038/tp.2012.132
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Demographic characteristics
| P | ||||||
|---|---|---|---|---|---|---|
| Age at death (years) | 48±11 (29–68) | 47±9 (30–65) | 42±12 (25–61) | 45±13 (25–62) | 0.540 | One-way ANOVA |
| Gender | 9 Male/6 female | 9 Male/6 female | 9 Male/6 female | 9 Male/6 female | — | — |
| PMI (h) | 23.7±9.9 (8–42) | 27.5±10.7 (7–47) | 32.5±16.1 (13–62) | 33.7±14.6 (12–61) | 0.147 | One-way ANOVA |
| Brain (pH) | 6.3±0.2 (5.8–6.6) | 6.2±0.2 (5.8–6.5) | 6.2±0.2 (5.8–6.5) | 6.2±0.3 (5.8–6.6) | 0.611 | One-way ANOVA |
| Side of brain | 7 Right/8 left | 6 Right/9 left | 8 Right/7 left | 6 Right/9 left | 0.864 | |
| Brain weight (g) | 1501±164 (1305–1840) | 1462±142 (1240–1740) | 1441±172 (1130–1690) | 1471±108 (1270–1640) | 0.739 | One-way ANOVA |
| Refrigeration interval (h) | 3.6±1.4 (1–6) | 7.9±5.5 (3–21) | 9.5±10 (2–39) | 8.5±7.2 (3–27) | 0.114 | One-way ANOVA |
| Storage days | 2257±234 (1950–2693) | 2353±290 (2005–2850) | 2540±172 (2143–2755) | 2540±233 (1987–2857) | 0.003 | One-way ANOVA |
| Age at onset (years) | — | 33.9±13.3 (11–54) | 21.5±8.3 (7–39) | 23.2±8.0 (13–42) | 0.003 | One-way ANOVA |
| Duration of disease (years) | — | 12.7±11.1 (1–42) | 20.1±9.7 (6–43) | 21.3±11.4 (5–45) | 0.068 | One-way ANOVA |
| Death by suicide | 15 No | 8 No/7 Yes | 6 No/9 Yes | 11 No/4 Yes | 0.181 | 2 |
| History of psychosis | — | 15 without | 11 with/4 without | 15 with | 0.100 | Fisher's test |
| Fluphenazine equivalent (mg) | 0 | 0 | 20 827±24 016 (0–60 000) | 52 267±62 062 (0–200 000) | 0.078 | Unpaired |
| 15–20 | 0 | 2 | 3 | 1 | 0.335 | |
| 21–25 | 6 | 3 | 2 | 3 | ||
| 26–30 | 5 | 8 | 7 | 3 | ||
| 31–35 | 1 | 1 | 1 | 4 | ||
| 36–40 | 1 | 0 | 2 | 2 | ||
| 41–45 | 2 | 1 | 0 | 2 | ||
| Never | 12 | 10 | 6 | 9 | 0.377 | |
| Current | 1 | 4 | 6 | 4 | ||
| Past | 2 | 1 | 3 | 2 | ||
| None/little/social | 14 | 11 | 7 | 10 | 0.056 | |
| Moderate use (current, past) | 1 | 0 | 5 | 2 | ||
| Heavy use (current, past) | 0 | 3 | 3 | 3 | ||
| Unknown | 0 | 1 | 0 | 0 | ||
| None/little/social | 11 | 9 | 4 | 7 | 0.156 | |
| Moderate use (current, past) | 4 | 1 | 3 | 3 | ||
| Heavy use (current, past) | 0 | 4 | 5 | 3 | ||
| Unknown | 0 | 1 | 3 | 2 | ||
| Yes | 4 | 5 | 3 | 5 | 0.534 | |
| No | 3 | 5 | 7 | 7 | ||
| Unknown | 8 | 5 | 5 | 3 | ||
Abbreviations: ANOVA, analysis of variance; BD, bipolar disorder; ETOHSEV, severity of alcohol abuse; MDD, major depressive disorder; PMI, post-mortem interval; SUBS, history of substance abuse; SUBSSEV, severity of substance abuse.
Values are expressed as means±s.d. (minimum−maximum).
One-way ANOVAs were used only among MDD, BD, and schizophrenia groups. History of SUBS: never, no history of use; current, drug and/or alcohol use at the time of death; past, a history of alcohol and/or drug use but not in the 6 months before death. Group differences in smoking at the time of death were analyzed after excluding unknown subjects.
χ2 Test was used among MDD, BD and schizophrenia groups.
Fisher's exact test and an unpaired t-test were used with the BD and schizophrenia groups.
Figure 1Effects of myelin inclusion or confounding factors on the human brain fatty acid (FA) composition. (A) Pearson's correlation coefficient matrix of 24 FAs for all available countable confounding factors of frontopolar cortex (FPC) (left, bottom) and inferior temporal cortex (ITC) (right, top) samples. Correlations are expressed by the respective color tiles. Note that none of the available countable confounding factors significantly affected FA composition, whereas the nine major FA concentrations (marked with an *) showed multicollinearity (|r|>0.8), probably due to inadvertent myelin inclusions. AGE, age at death; ONSET, age at onset; DUR, duration of disease (years); FLU, fluphenazine equivalent (mg); PH, brain pH; WEIGHT, brain weight (gram); PMI, post-mortem interval (hours); STORAGE, frozen storage (days); and OBESITY, obesity index. Letters in the matrix (A and B) indicate the position of graphs in panel C (for example, a=Figure 1Ca). (B) Rearranged correlation coefficient matrix of the marked FAs and myelin factors (MFs) for FPC (left, bottom) and ITC (right, top) samples. (C) Correlation between 22:6n-3 (docosahexaenoic acid (DHA)) concentration (mol%) and (a) 24:1n-9 concentration (mol%), (b) age at death, (c) PMI, (d) pH, (e) brain weight, (f) frozen storage days, (g) age at onset and (h) duration of disease. Note that only the 24:1n-9 concentrations correlated significantly with those of DHA (P<0.0001), suggesting that the concentrations of one FA (for example, DHA) can be predicted by other FA concentrations (for example, 24:1n-9) (see the results of multiple regression analyses in Supplementary Table 2).
Effects of uncountable confounding factors on the human brain FA composition
| P | P | |||||
|---|---|---|---|---|---|---|
| Gender (60) | 0.678 | 0.692 | 0.826 | 0.692 | 0.649 | 0.865 |
| Side of Brain (60) | 0.546 | 1.212 | 0.296 | 0.591 | 1.011 | 0.479 |
| Death by Suicide (60) | 0.572 | 1.091 | 0.399 | 0.570 | 1.101 | 0.391 |
| SUBS (60) | 0.531 | 0.528 | 0.212 | 0.502 | 0.582 | 0.975 |
| SUBSSEV (59) | 0.521 | 0.530 | 0.989 | 0.492 | 0.586 | 0.973 |
| ETOHSEV (54) | 0.331 | 0.861 | 0.701 | 0.339 | 0.838 | 0.734 |
| Psychosis (60) | 0.641 | 0.816 | 0.695 | 0.709 | 0.600 | 0.903 |
| 0.023 | 3.489 | 0.094 | 1.662 | |||
| Sch vs Cont (30) | 0.263 | 0.583 | 0.831 | 0.419 | 0.289 | 0.989 |
| AD vs Cont (45) | 0.061 | 12.808 | 0.204 | 3.253 | ||
| AD vs Sch (45) | 0.054 | 14.667 | 0.176 | 3.894 | ||
| BD vs MDD (30) | 0.177 | 0.969 | 0.579 | 0.307 | 0.470 | 0.904 |
Abbreviations: AD, affective disorders (including BD and MDD); BD, bipolar disorder; Cont, normal control; ETOHSEV, severity of alcohol abuse; FA, fatty acid; FPC, frontopolar cortex; ITC, inferior temporal cortex; MDA, multiple discriminant analysis; MDD, major depressive disorder; Sch, schizophrenia; SUBS, history of substance abuse; SUBSSEV, severity of substance abuse.
MDA was used for the analyses. P-values ≤0.05 are shown in bold.
Numbers within parentheses indicate numbers of samples analyzed.
Figure 2Top five fatty acid (FA) metabolic abnormalities in the affective disorder frontopolar cortex (FPC). (a) 22:5n-3. As the myelin factors (MFs) (myelin proportions in the cortical homogenates) increased, 22:5n-3 accumulated in the affective disorder (bipolar disorder (BD), major depressive disorder (MDD)), but not in the schizophrenia (Sch) FPC samples. (b) 18:3n-6. Similar accumulation of 18:3n-6 was observed only in the affective disorder FPC samples. Arrows indicate data from subjects with MDD who had not been prescribed antidepressant medications at around the time of death (see Supplementary Table 1), suggesting that such medications may not affect these findings. (c) 18:1n-9. Myelin-abundant FA, 18:1n-9, was significantly reduced only in the affective disorder FPC samples, particularly those having more myelin. (c′) Conventional comparison of 18:1n-9 concentrations. Note that, without MFs, we were deprived of information regarding the relationship between myelin and FA concentration. Furthermore, a statistically significant difference was only found between Sch and BD (P=0.03). (d) The 18:1n-9/18:0 ratios. (e). The 20:0/18:0 ratios. These two ratios were decreased in the mood disorder FPC samples, especially those having more myelin. (f) Summary of the FA metabolic abnormalities in the affective disorder FPC samples. Top five abnormalities found in this study are shown in red. Other significant, but less specific FAs, as well as their corresponding metabolic abnormalities, were also found in the affective disorder FPC samples (colored pink, see Supplementary Tables 4 and 5). Arrows indicate desaturase activities, downward arrowheads elongase activities, and an upward arrowhead β-oxidation. Several FA concentrations or their metabolic activities were undetectable in this study, and are therefore parenthesized. PUFAs, polyunsaturated FAs.
Figure 3The similar fatty acid (FA) metabolic abnormalities in affective disorder brains and rat hippocampi chronically treated with antidepressants. (a) 22:5n-3 in the inferior temporal cortex (ITC). In contrast to the frontopolar cortex (FPC) (Figure 2a), the concentration of 22:5n-3 decreased significantly in the affective disorder ITC. (b) 22:5n-3 in the rat hippocampus chronically treated with or without antidepressants. Chronic antidepressant treatment significantly reduced the concentrations of 22:5n-3 in the rat hippocampus. (c, d) 20:1n-9/18:1n-9 ratios in the FPC and rat hippocampus. As the myelin fibers (MFs) (myelin proportions in the cortical homogenates) increased, these ratios increased and became abnormally upregulated in the affective disorder FPC (c), as well as in the rat hippocampus chronically treated with antidepressants (d).